Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

NCT ID: NCT01284517

Last Updated: 2013-11-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

356 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective among patients with bipolar I depression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bipolar I Depression Lurasidone Latuda

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lurasidone 20-120 mg flexible dose

Group Type EXPERIMENTAL

Lurasidone

Intervention Type DRUG

Tablets 20-120 mg, PM dosing,daily for 6 weeks

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Equivalent to Lurasidone dosing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lurasidone

Tablets 20-120 mg, PM dosing,daily for 6 weeks

Intervention Type DRUG

Placebo

Equivalent to Lurasidone dosing

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Latuda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide written informed consent and is 18 to 75 years of age inclusive.
2. Meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.
3. Has a lifetime history of at least one bipolar manic or mixed manic episode.
4. Currently being treated with lithium or divalproex or willing to begin treatment with lithium or divalproex.
5. Not pregnant or nursing and is not planning pregnancy within the projected duration of the study.
6. Females of reproductive potential agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after
7. Good physical health on the basis of medical history, physical examination, and laboratory screening.

Exclusion Criteria

1. Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
2. Any chronic organic disease of the CNS (other than Bipolar I Disorder).
3. Hospitalization for a manic or mixed episode within the past two months.
4. Used investigational compound within past 6 months.
5. Clinically significant history of alcohol or substance abuse within the past 3 months or alcohol or substance dependence within the past 12 months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director, MD

Role: STUDY_DIRECTOR

Sumitomo Pharma America, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Innovations, Inc.

Costa Mesa, California, United States

Site Status

Clinical Innovations Inc.

Riverside, California, United States

Site Status

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status

Sharp Mesa Vista Hospital

San Diego, California, United States

Site Status

Clinical Innovations inc.

Santa Ana, California, United States

Site Status

Collaborative Neuroscience Network

Torrance, California, United States

Site Status

Colorado Clinical Trials Inc.

Highlands Ranch, Colorado, United States

Site Status

Accurate Clinical Trials

Kissimmee, Florida, United States

Site Status

Clinical Neuroscience Solutions Inc.

Orlando, Florida, United States

Site Status

Northwest Behavioral Research Center

Roswell, Georgia, United States

Site Status

Institute for Behavioral Medicine LLC

Smyrna, Georgia, United States

Site Status

Precise Research Centers

Flowood, Mississippi, United States

Site Status

Village Clinical Research Inc.

New York, New York, United States

Site Status

Medical & Behavioral Health Research

New York, New York, United States

Site Status

Zarzar Psychiatric Associates, PLLC

Raleigh, North Carolina, United States

Site Status

Summit Research Network (Oregon) Inc.

Portland, Oregon, United States

Site Status

Lehigh Valley Hospital

Allentown, Pennsylvania, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Memphis, Tennessee, United States

Site Status

FutureSearch Clinical Trials, LP

Dallas, Texas, United States

Site Status

Pillar Clinical Research

Dallas, Texas, United States

Site Status

Red Oak Psychiatry Associates, PA

Houston, Texas, United States

Site Status

Summit Research Network (Seattle) LLC

Seattle, Washington, United States

Site Status

Clinical Research Group Edmonton Inc

Edmonton, Alberta, Canada

Site Status

Okanagan Clinical Trials

Kelowna, British Columbia, Canada

Site Status

Pierre-Janet Hospital

Gatineau, Quebec, Canada

Site Status

Hopital Louis-H Lafontaine

Montreal, Quebec, Canada

Site Status

Centro de Investigaciones y Proyectos en Neurociencias CIPNA

Barranquilla, , Colombia

Site Status

Centro de Investigacion y Atencion para la Salud Mental

Bogotá, , Colombia

Site Status

CISNE - UIC Campo Abierto

Bogotá, , Colombia

Site Status

Hospital Mental de Antioquia

Cali, , Colombia

Site Status

Psychiatricka ambulance

Brno-mesto, , Czechia

Site Status

Vojenska nemocnice Olomouc

Olomouc, , Czechia

Site Status

Clintrial, s.r.o.

Prague, , Czechia

Site Status

Psychiatry Trial s.r.o.

Prague, , Czechia

Site Status

Brain Mind Behavior Neuroscience Research Institute

Visakhapatnam, Andh Prad, India

Site Status

Shanti Nursing Home

Kanchanpalli, Aurangabad, Maharashtra, India

Site Status

SBKS Medical College and Hospital, Brij Psychiatry Hospital

Vadodara, Gujarat, India

Site Status

Abhaya Hospital Psychiatry

Bangalore, Karna, India

Site Status

K.S. Hegde Medical Academy

Mangalore, Karna, India

Site Status

Poona Hospital & Research Center

Pune, Mahara, India

Site Status

Mahatma Ghandi Institute of Medical Sciences

Wardha, Mahara, India

Site Status

Mental Health Care & Research

Jaipur, Rajasthan, India

Site Status

R.K. Yadav Memorial Mental Health & De-addiction Hospital

Jaipur, Rajasthan, India

Site Status

Mahendru Psychiatric Center

Kanpur, Uttar Prad, India

Site Status

Chatrapati Shau Maharaj Medical University

Lucknow, Utter Prad, India

Site Status

Ongata Hospital

Hachioji-shi, , Japan

Site Status

Kohnodai Hospital, National Center for Global Health & Medicine

Ichikawa, , Japan

Site Status

National Hospital Organization Hizen Psychiatric Center

Kanzaki-gun, , Japan

Site Status

National Center of Neurology & Psychiatry

Kodaira-shi, , Japan

Site Status

Asakayama General Hospital

Sakaishi, , Japan

Site Status

Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital

Takatsuki, , Japan

Site Status

Neuromeda JSC

Kaunas, , Lithuania

Site Status

Ziegzdriai Mental Hospital, Public Institution

Kaunas, , Lithuania

Site Status

Silutes Mental Health & Psychtherapy Center, JSC

Šilutė, , Lithuania

Site Status

Seskines Outpatient Clinic, Public Institution

Vilnius, , Lithuania

Site Status

Zirmunai Mental Health Center, Public Institution

Vilnius, , Lithuania

Site Status

Hospital Nacional Arzobispo Loayza

Lima, , Peru

Site Status

Hospital Nacional Hipolito Unanue

Lima, , Peru

Site Status

Clinica Vesalio

Lima, , Peru

Site Status

Centrum zdravia R. B. K. s.r.o.

Bardejov, , Slovakia

Site Status

Bojniciach

Bojnice, , Slovakia

Site Status

Psychiatricka ambulancia Mentum s.r.o.

Bratislava, , Slovakia

Site Status

FNsP Bratislava, Nemocnica Ruzinov

Bratislava, , Slovakia

Site Status

Nemocnica s poliklinikou Liptovsky Milulas

Liptovský Mikuláš, , Slovakia

Site Status

PsychoLine s.r.o.

Rimavská Sobota, , Slovakia

Site Status

Nemocnica s poliklikou Sv. Barbory

Rožňava, , Slovakia

Site Status

Pro mente sana

Trenčín, , Slovakia

Site Status

Kherson Regional Psychiatric Hospital

Kherson, Vil Stepanivka, Ukraine

Site Status

Dnipropetrovsk Regional Clinical Hospital named Mechnikov

Dnipropetrovsk, , Ukraine

Site Status

Com Inst Knipropetrovsk Reg Cl Psych Hospital DSMA

Dnipropetrovsk, , Ukraine

Site Status

St. In. Inst of Neurol, Psych, and Narcol of the AMSU

Kharkiv, , Ukraine

Site Status

Kyiv City Psychoneurological Hospital #2

Kyiv, , Ukraine

Site Status

Lviv Regional Clinical Psychiatric Hospital

Lviv, , Ukraine

Site Status

Ternopil Regional Municipal Dispensary, Narcology Dept.

Ternopil, , Ukraine

Site Status

Zapor. Reg. CI Hospital, Zaporizhzhia SMU

Zaporizhzhya, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China United States Canada Colombia Czechia India Japan Lithuania Peru Slovakia Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Hopkins SC, Tomioka S, Szabo ST, Koblan KS. A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression. Contemp Clin Trials. 2024 Oct;145:107644. doi: 10.1016/j.cct.2024.107644. Epub 2024 Aug 3.

Reference Type DERIVED
PMID: 39098761 (View on PubMed)

Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016 Jul;78:86-93. doi: 10.1016/j.jpsychires.2016.03.012. Epub 2016 Mar 31.

Reference Type DERIVED
PMID: 27089521 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-019778-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D1050292

Identifier Type: -

Identifier Source: org_study_id